pramiconazole

Pramiconazole is a triazole antifungal agent that was under development for the treatment of acute skin and mucosal fungal infections, including dermatomycoses, onychomycosis, seborrheic dermatitis, and pityriasis versicolor. It acts by selectively inhibiting fungal cell membrane ergosterol synthesis through potent inhibition of the enzyme sterol 14-alpha-demethylase (a cytochrome P450 enzyme), leading to increased cell permeability and destruction of fungal cells. Pramiconazole demonstrated broad-spectrum activity against dermatophytes (such as Trichophyton spp., Microsporum canis) and yeasts (including Candida spp. and Malassezia spp.), with in vitro potency comparable or superior to ketoconazole and itraconazole. The drug was developed primarily as an oral formulation, showed rapid absorption, a long half-life suitable for once-daily dosing, and was generally well tolerated in early clinical trials. Development was initiated by Barrier Therapeutics but later suspended after acquisition by Stiefel Laboratories (a GlaxoSmithKline company), with no further advancement reported[1][3][4][5][6][7].

Other names

pramiconazoleAzoline